Posts Tagged ‘innovation’

We are only halfway through ADA2025 in Chicago and already the flood of information about new drugs for obesity like orforglipron, amycretin, and a host of others leaves us feeling like we have been sprayed down by a fire hose. Much more will be coming at us in the next two days. Orforglipron and Other […]

We are landing in Chicago for the ADA Scientific Sessions and you can be sure that a veritable river of news about obesity will be flowing. Everything from basic science to innovative treatment and pragmatic approaches for clinical care and policy will be offered up by this meeting of the American Diabetes Association. This promises […]

In drug therapy for obesity, all of the excitement about GLP-1s and now amylin analogs has focused on regulation of eating behaviors. But, in fact, this is just one part of the process for regulating metabolic function and adiposity. Until now, we have seen little success in developing safe and effective medicines that alter the […]

As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors. Then yesterday […]

Yesterday, Metsera presented investors with topline data from phase one studies of a new amylin analog for obesity that promises monthly dosing. This is an early stage drug known only by its code name – MET-233i. Metsera is a young biotech company, founded in 2022. The big news here: 8.4% placebo-subtracted weight loss after 36 […]

The first shall be last and the last shall be first. Right now, it seems that Novo Nordisk, the pharmaceutical company that was first to commit and break through with a major advance in obesity is now falling behind Eli Lilly and Company. This is a story of risk, reward, and caution in the competition […]

Regeneron announced tantalizing results for the combination of trevogrumab with semaglutide for losing fat while preserving muscle. With the combination of these two drugs, it appears that individuals might lose more fat mass and less muscle mass than with semaglutide alone. In short, the promise is for a better quality of weight loss, leaving people […]

“Today, we salute you, Lars Fruergaard Jørgensen,” writes Dave Knapp on his widely-read substack commentary. After a startling transition in leadership at Novo Nordisk, Jørgensen is now the outgoing CEO. Jørgensen is the CEO who guided the successful launch of Ozempic and Wegovy. He made the company into one of the most valuable in Europe. […]

The first ever estimates of the economic impact of cuts to U.S. government-funded research are out from economists at American University in Washington. The current administration has already frozen billions of dollars in research funding. The president’s budget proposal last week called for cutting funding to the National Science Foundation by more than half. The […]

More than a decade ago, targeting amylin receptors for treating obesity looked like hot opportunity. Amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells, plays a role in regulating satiety and food intake. An amylin analog, pramlintide, gained FDA approval for treating diabetes. But efforts to develop it for treating obesity never quite […]